Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
$2.40
-0.4%
$2.54
$0.96
▼
$3.16
$56.90M0.0287,918 shs152,852 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$0.85
+2.0%
$1.03
$0.81
▼
$2.46
$13.95M1.65123,539 shs105,817 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$2.82
-4.1%
$7.11
$2.77
▼
$20.56
$57.13M1.91.07 million shs1.04 million shs
XBiotech Inc. stock logo
XBIT
XBiotech
$1.73
-2.8%
$2.06
$1.71
▼
$2.73
$54.27M0.7678,010 shs60,736 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
0.00%-1.63%+2.99%-15.73%+103.38%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+0.97%-11.96%-19.56%-35.15%-12.38%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
+2.08%-28.29%-51.32%-76.90%-82.51%
XBiotech Inc. stock logo
XBIT
XBiotech
-3.78%-9.64%-16.04%-22.94%-27.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
$2.40
-0.4%
$2.54
$0.96
▼
$3.16
$56.90M0.0287,918 shs152,852 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$0.85
+2.0%
$1.03
$0.81
▼
$2.46
$13.95M1.65123,539 shs105,817 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$2.82
-4.1%
$7.11
$2.77
▼
$20.56
$57.13M1.91.07 million shs1.04 million shs
XBiotech Inc. stock logo
XBIT
XBiotech
$1.73
-2.8%
$2.06
$1.71
▼
$2.73
$54.27M0.7678,010 shs60,736 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
0.00%-1.63%+2.99%-15.73%+103.38%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+0.97%-11.96%-19.56%-35.15%-12.38%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
+2.08%-28.29%-51.32%-76.90%-82.51%
XBiotech Inc. stock logo
XBIT
XBiotech
-3.78%-9.64%-16.04%-22.94%-27.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
1.00
SellN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
2.25
Hold$10.001,072.06% Upside
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
3.00
Buy$22.33691.96% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest MRKR, TNXP, BOLD, and XBIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/13/2026
XBiotech Inc. stock logo
XBIT
XBiotech
UpgradeSell (E+) ➝ Sell (D-)
11/13/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
DowngradeStrong-Buy ➝ Hold
10/30/2026
XBiotech Inc. stock logo
XBIT
XBiotech
DowngradeSell (D-) ➝ Sell (E+)
10/27/2026
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
Reiterated RatingSell (D-)
10/26/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Reiterated RatingSell (E+)
10/26/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Initiated CoverageBuy$18.00
10/20/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Reiterated RatingStrong-Buy
10/19/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
10/16/2026
XBiotech Inc. stock logo
XBIT
XBiotech
UpgradeSell (E+) ➝ Sell (D-)
10/15/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
UpgradeHold ➝ Strong-Buy
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/AN/AN/AN/A$2.61 per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$3.55M4.01N/AN/A$1.01 per share0.84
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$13.11M4.18N/AN/A$10.27 per share0.27
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/A$4.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
-$58.20M-$2.47N/AN/AN/AN/A-70.98%-50.99%N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$12.16M-$0.39N/AN/AN/AN/A-60.00%-50.22%N/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$124.02M-$12.24N/AN/AN/A-420.45%-80.97%-70.18%N/A
XBiotech Inc. stock logo
XBIT
XBiotech
-$45.54M-$1.43N/AN/AN/AN/A-33.03%-31.57%N/A

Latest MRKR, TNXP, BOLD, and XBIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.1167-$0.10+$0.0167-$0.10$2.12 million$1.29 million
11/12/2026Q3 2026
XBiotech Inc. stock logo
XBIT
XBiotech
$0.02-$0.15-$0.17-$0.15$7.00 millionN/A
11/10/2026Q3 2026
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A-$0.23N/A-$0.23N/AN/A
11/9/2026Q3 2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$2.39-$2.89-$0.50-$2.89$16.32 million$17.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A
33.97
33.97
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.03
6.03
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/A
4.57
4.47
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
39.51
33.15

Institutional Ownership

CompanyInstitutional Ownership
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
82.26%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
23.10%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
5.70%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.00%
XBiotech Inc. stock logo
XBIT
XBiotech
21.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
2823.61 million18.16 millionNo Data
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
516.67 million15.72 millionNot Optionable
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
14219.43 million19.04 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
8730.49 million24.06 millionOptionable

Recent News About These Companies

XBiotech: Q4 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Boundless Bio stock logo

Boundless Bio NASDAQ:BOLD

$2.40 -0.01 (-0.41%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 +0.02 (+0.96%)
As of 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$0.85 +0.02 (+1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$0.85 +0.00 (+0.09%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Tonix Pharmaceuticals stock logo

Tonix Pharmaceuticals NASDAQ:TNXP

$2.82 -0.12 (-4.08%)
Closing price 04:00 PM Eastern
Extended Trading
$2.87 +0.05 (+1.77%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$1.73 -0.05 (-2.81%)
Closing price 04:00 PM Eastern
Extended Trading
$1.76 +0.03 (+1.68%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.